A scoping review of factors influencing the implementation of liquid biopsy for cancer care

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: Feb. 12, 2025

Abstract Background Liquid biopsy (LB) offers a promising, minimally invasive alternative to traditional tissue biopsies in cancer care, enabling real-time monitoring and personalized treatment. Despite its potential, the routine implementation of LB clinical practice faces significant challenges. This scoping review examines barriers facilitators influencing liquid into standard care. Methods Four academic databases (PubMed, Scopus, Embase, Web Science) were systematically searched without language restrictions. We included peer-reviewed articles that published between January 2019 March 2024 focused on care or described implementation. Data relevant objective, including key article characteristics; implementation; recommendations for advancement optimisation; extracted analysed using thematic visual network analyses. Results The majority narrative (84%), with most from China (24.2%) United States (20%). Thematic analysis identified four main categories their associated care: (1) Laboratory personnel requirements; (2) Disease specificity; (3) Biomarker-based biopsy; (4) Policy regulation. concentrated pre-analytical phase, highlighting lack standardization technologies outcomes. Conclusions Through implementation, we present an integrated tool designed encourage testing methods guidelines field.

Language: Английский

---

Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance

Cancer Investigation, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 22

Published: Feb. 24, 2025

Genomic sequencing of tumours improves patient outcomes through implementation precision oncology. At present, genomic testing is mainly confined to research settings, with samples sent biopharmaceutical companies for analysis. The ever-expanding catalogue approved targeted therapies has created an urgent unmet need local facilities, enable upscaling testing. Here, we compare the (IonTorrent™) and commercial (Foundation Medicine) collected from 30 cancer patients in plasma tissue samples. Overall concordance was high both (98%) (94.2%). Variants identified by platforms had a strong correlation variant allele frequencies (VAF%): plasma: r = 0.99 p < 0.0001, tissue: 0.91 0.0001. However, numerous low VAF% variants resulted positive percentage agreement (tissue 78.8% 16.1%) predictive values 56.3% 71.4%). Local demonstrated higher fidelity detecting fusions but indels. Overall, this study supports use routine molecular diagnostics highlights outstanding issues before widespread implementation. Processing detected at limit detection assays needs be addressed. Construction gene panels requires careful consideration, including incorporation markers instability.

Language: Английский

---

Multicancer early detection testing: Guidance for primary care discussions with patients

Cancer, Journal Year: 2025, Volume and Issue: 131(7)

Published: April 1, 2025

Multicancer early detection (MCED) tests are an emerging technology for cancer screening. MCED can detect signals from multiple cancers concurrently in biological samples such as blood, urine, saliva, or other bodily fluids. Some suggest the most likely origin, whereas others report detected somewhere body. Although some currently commercially available, none approved by Food and Drug Administration endorsed any clinical practice guideline recommendation. Most insurance companies do not cover testing. have yet been evaluated safety effectiveness randomized controlled trials. Because patients already asking test prescriptions interpretation of results acquired elsewhere, clinicians should be prepared to discuss what is known about benefits, risks, uncertainties testing, including performance characteristics screening populations preferred follow-up strategies positive results. At this time, feel obligated initiate discussions testing with their patients. However, engage who inquire getting tested previous shared decision-making, take opportunity offer help complete age- sex-appropriate guideline-recommended screenings. In article, current evidence issues around summarized, a framework decision-making provided.

Language: Английский

---

Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas

Cancers, Journal Year: 2024, Volume and Issue: 16(10), P. 1881 - 1881

Published: May 15, 2024

The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating response and detecting early relapse, necessitating exploration novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool monitoring efficacy predicting outcomes B-NHL following CAR-T therapy. By overcoming limitations conventional imaging modalities, ctDNA assessments offer valuable insights into dynamics, molecular mechanisms resistance, detection relapse. Integration clinical practice holds promise personalized therapeutic strategies, guiding development targeted therapies, enhancing patient outcomes. standardization assay methodologies consensus on metrics are imperative to unlock full potential management B-NHL. Prospective validation trials necessary establish its role as complementary decision aid.

Language: Английский

---

Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(7), P. 6533 - 6565

Published: June 27, 2024

Technological advancements in cell-free DNA (cfDNA) liquid biopsy have triggered exponential growth numerous clinical applications. While cfDNA-based has made significant strides personalizing cancer treatment, the exploration and translation of epigenetics to practice is still nascent. This comprehensive review seeks provide a broad yet in-depth narrative present status cfDNA its associated challenges. It highlights potential technologies with hopes enhancing translation. The momentum recent years propelled forefront molecular biology. We only begun reveal true both our understanding disease leveraging diagnostic therapeutic domains. Recent applications epigenetics-based revolve around methylation screening early detection, leading development multi-cancer detection tests capability pinpoint tissues origin. application minimal residual disease, monitoring, surveillance are at their initial stages. A notable advancement fragmentation patterns analysis created new avenue for epigenetic biomarkers. However, widespread many challenges, including biomarker sensitivity, specificity, logistics infrastructure personnel, data processing, handling, results interpretation, accessibility, cost effectiveness. Exploring translating technology can transform perception prevention management. great precision oncology revolutionize conventional ways monitoring treatment response, surveillance, drug development. Adapting implementation workflow local policy worldwide developing point-of-care testing holds overcome global disparity improve outcomes.

Language: Английский

---

Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center

Cancers, Journal Year: 2024, Volume and Issue: 16(14), P. 2505 - 2505

Published: July 10, 2024

Liquid biopsy is rapidly becoming an indispensable tool in the oncologist's arsenal; however, this technique remains elusive a publicly funded healthcare system, and real-world evidence needed to demonstrate utility feasibility. Here, we describe first experience of in-house point care liquid program at Canadian community hospital. A retrospective review consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. initiated discretion clinicians. Sequencing followed workflow using Genexus™ integrated sequencer Oncomine precision assay, performed by histotechnologists. Results were reported attending pathologist. Eligible charts reviewed for outcomes interest, including intent biopsy, results turnaround time from blood draw available. total 124 cases, with confirmed or suspected cancer, between January 2021 November 2023. The median 3 business days (range 1-12 days). sensitivity biopsies 71%, compared tissue testing matched available comparison. Common mutations included

Language: Английский

---

An Interdisciplinary Perspective on Improving Cancer Care in the State of Mississippi as an Example of Cancer Care Improvements in the Global South

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Cancer disparities, a critical public health issue, particularly in states such as Mississippi, where socioeconomic factors significantly influence outcomes, require our collective attention. This paper delves into the multifaceted nature of cancer disparities through macro-level analysis data, specifically focusing on Mississippi microcosm broader national and global trends. Two key indices, Socio-Demographic Index (SDI) Social Deprivation (SDeI), provide valuable insights. The former offers understanding that shape outcomes. latter quantifies disadvantages small areas, identifying regions need scientific, policy, administrative support. poor care (CC) outcomes are well documented detailed here. However, SDI SDeI data not yet available Mississippi. With biological, technological, clinical research design advancements other new innovative strategies emerging past decade CC, 'leapfrogging' CC is within reach. To achieve this goal, an interdisciplinary approach (IDA) addressing solving challenges faced required. IDA team must include disciplines can determine for tie those findings to successfully apply technological advances innovations efficiently cost-effectively by building infrastructure developing implementation strategies. serve pilot demonstration project will also help similar United States, Global South.

Language: Английский

---

Liquid biopsy: an emerging field with new opportunities for cancer diagnosis and prognosis

Asia-Pacific Journal of Oncology, Journal Year: 2025, Volume and Issue: unknown, P. 9 - 17

Published: Jan. 14, 2025

Cancer grades among the deadliest diseases, globally causing death of a over million people each year. Early diagnosis has been considered ideal for efficient treatment as during later stages chances become limited. However, gold standard tissue biopsy various limitation instance, late-stage and its intrusive operation making it unfit repeated sampling. Scientists are passionately looking new technologies techniques cancer prognosis. Liquid emerged diagnostic prognostic tool cancer, that relies on body fluids to identify biomarkers cancer. It offers advantages like non-invasive operation, timely detection, amenable sampling, covers tumor heterogeneity. Wide attention garnered by liquid is undergoing rapid progress in list target biomarkers. The most common circulating cells, DNA, exosomes, educated platelets, non-coding RNAs (miRNA, lncRNA etc.). Each these have unique advantages, indeed technology future with clinical utility. In this article, we tried provide thorough introduction markers, highlighted deployed biopsy, briefly overview their implications indispensable entities diverse types Moreover, discussed prospects revolutionary realm treatment.

Language: Английский

---

Analytical Validation of the Labcorp Plasma Complete Test, a Cell-free DNA Comprehensive Genomic Profiling Tool for Precision Oncology

Journal of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis

The Oncologist, Journal Year: 2025, Volume and Issue: 30(2)

Published: Feb. 1, 2025

Abstract Background Predicting early treatment response in advanced non-small cell lung cancer (NSCLC) is challenging. Longitudinal monitoring of circulating tumor DNA (ctDNA) can track to treatments like immune checkpoint blockade (ICB) and correlate with outcomes. This meta-analysis evaluated whether ctDNA clearance or decrease associated improved survival across various settings NSCLC. Methods A systematic review MEDLINE, EMBASE, Cochrane databases (up April 2024) identified studies evaluating the impact kinetics on outcomes non-curative NSCLC settings. Pooled hazard ratios (HR) for progression-free (PFS) overall (OS) were calculated using a random effects model. Results We included 32 3047 patients receiving systemic therapies such as targeted therapy (TT), ICB, chemotherapy. Meta-analysis 31 showed that decrease/clearance was linked PFS (HR: 0.32 [0.26, 0.40], I² = 63%, P &lt; .01). Subgroup analysis indicated strong benefits from 0.27 [0.20, 0.36]). Similar improvements seen undergoing 0.34) ICB 0.33). Analysis 25 revealed significant association between reduction better OS 0.31 [0.23, 0.42], 47%, findings consistent both TT 0.41) 0.32). Sensitivity demonstrated clearance/decrease consistently study designs methods. There no variation based subtypes, smoking status, sex. Conclusion Plasma diagnosed ICB.

Language: Английский

---